GlassScriptPhysician profile
Robert Paul Snyder
NPI 1932598414
$16,663.26
in general payments reported to CMS, 2019-2025
56 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,331 · 2020: $1,835 · 2021: $3,526 · 2022: $2,762 · 2023: $2,661 · 2024: $3,103 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,131 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.70 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,651.73 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,536.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,237.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $869.86 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $833.71 | 2019-2024 | |
| Astellas Pharma US INC | $706.82 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $621.73 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $618.28 | 2019-2022 | |
| Daiichi Sankyo INC. | $608.78 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $596.05 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.94 | 2019-2024 | Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.92 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $403.74 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $399.42 | 2019-2022 | |
| Abbott Laboratories | $385.02 | 2021-2024 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $349.86 | 2020-2024 | |
| Amgen INC. | $301.09 | 2020-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $300.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $259.71 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $258.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.93 | 2021-2024 | |
| Alkermes, INC. | $213.72 | 2021-2025 | Vivitrol, Vivitrol |
| Allergan, INC. | $185.24 | 2019-2020 | |
| Dexcom, INC. | $180.02 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $171.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.92 | 2019-2025 | Trintellix |
| Nestle Healthcare Nutrition INC. | $132.06 | 2020-2023 | |
| Lundbeck LLC | $129.10 | 2022-2024 | Rexulti, Vyepti |
| Exact Sciences Corporation | $128.55 | 2023-2024 | Cologuard Collection Kit |
| Electromed, INC. | $100.56 | 2022-2025 | Smartvest |
| Indivior INC. | $97.41 | 2021-2024 | Sublocade |
| Medtronic, INC. | $88.60 | 2025 | Inceptiv |
| Axsome Therapeutics, INC. | $85.07 | 2024-2025 | Auvelity |
| Antares Pharma, INC. | $67.25 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Kowa Pharmaceuticals America, INC. | $61.18 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.87 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $56.48 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $55.46 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $49.59 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $41.81 | 2019-2024 | Nuzyra |
| Kiniksa Pharmaceuticals, LTD. | $34.88 | 2023 | Arcalyst |
| Shield Therapeutics INC | $32.02 | 2023-2024 | Accrufer |
| Insulet Corporation | $30.99 | 2021-2022 | |
| Biogen, INC. | $29.52 | 2021-2025 | Spinraza |
| Ardelyx, INC. | $28.42 | 2024 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $26.36 | 2022 | |
| Ucb, INC. | $25.41 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.70 | 2019 | |
| Boston Scientific Corporation | $24.45 | 2024 | Watchman Access System |
| Esperion Therapeutics, INC. | $23.87 | 2020 | |
| Avanir Pharmaceuticals, INC. | $23.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.74 | 2023 | Nuedexta |
| Seqirus USA INC | $17.12 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.45 | 2024 | Voquezna |
| Assertio Therapeutics, INC. | $14.69 | 2019 | |
| Alfasigma USA, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.